Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Gender differences in Community-acquired Pneumonia.

Barbagelata E, Cillóniz C, Dominedò C, Torres A, Nicolini A, Solidoro P.

Minerva Med. 2020 Mar 12. doi: 10.23736/S0026-4806.20.06448-4. [Epub ahead of print]

PMID:
32166931
2.

Community-Acquired Pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Guidelines. 2020 Update.

Menéndez R, Cilloniz C, España PP, Almirall J, Uranga A, Méndez R, Rigau D, Torres A.

Arch Bronconeumol. 2020 Mar 2. pii: S0300-2896(20)30040-5. doi: 10.1016/j.arbres.2020.01.014. [Epub ahead of print] English, Spanish.

PMID:
32139236
3.

Community-acquired pneumonia in critically ill very old patients: a growing problem.

Cillóniz C, Dominedò C, Pericàs JM, Rodriguez-Hurtado D, Torres A.

Eur Respir Rev. 2020 Feb 19;29(155). pii: 190126. doi: 10.1183/16000617.0126-2019. Print 2020 Mar 31. Review.

4.

Advances in molecular diagnostic tests for pneumonia.

Cilloniz C, Liapikou A, Torres A.

Curr Opin Pulm Med. 2020 Feb 13. doi: 10.1097/MCP.0000000000000668. [Epub ahead of print]

PMID:
32068574
5.

Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain.

Bassetti M, Russo A, Cilloniz C, Giacobbe DR, Vena A, Amaro R, Graziano E, Soriano A, Torres A.

Int J Antimicrob Agents. 2020 Feb 14:105921. doi: 10.1016/j.ijantimicag.2020.105921. [Epub ahead of print]

PMID:
32061999
6.

Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators.

Cillóniz C, Menéndez R, García-Vidal C, Péricas JM, Torres A.

Med Sci (Basel). 2020 Jan 25;8(1). pii: E6. doi: 10.3390/medsci8010006.

7.

Can Artificial Intelligence Improve the Management of Pneumonia.

Chumbita M, Cillóniz C, Puerta-Alcalde P, Moreno-García E, Sanjuan G, Garcia-Pouton N, Soriano A, Torres A, Garcia-Vidal C.

J Clin Med. 2020 Jan 17;9(1). pii: E248. doi: 10.3390/jcm9010248. Review.

8.

Programmed 'disarming' of the neutrophil proteome reduces the magnitude of inflammation.

Adrover JM, Aroca-Crevillén A, Crainiciuc G, Ostos F, Rojas-Vega Y, Rubio-Ponce A, Cilloniz C, Bonzón-Kulichenko E, Calvo E, Rico D, Moro MA, Weber C, Lizasoaín I, Torres A, Ruiz-Cabello J, Vázquez J, Hidalgo A.

Nat Immunol. 2020 Feb;21(2):135-144. doi: 10.1038/s41590-019-0571-2. Epub 2020 Jan 13.

PMID:
31932813
9.

Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning.

Garcia-Vidal C, Cillóniz C, Torres A.

Eur Respir J. 2019 Dec 12;54(6). pii: 1902111. doi: 10.1183/13993003.02111-2019. Print 2019 Dec. No abstract available.

PMID:
31831676
10.

Reply to Dr. Daniel Musher.

Cilloniz C, Torres A.

J Infect Dis. 2019 Dec 12. pii: jiz655. doi: 10.1093/infdis/jiz655. [Epub ahead of print] No abstract available.

PMID:
31829412
11.

A multicentre analysis of Nocardia pneumonia in Spain: 2010-2016.

Ercibengoa M, Càmara J, Tubau F, García-Somoza D, Galar A, Martín-Rabadán P, Marin M, Mateu L, García-Olivé I, Prat C, Cilloniz C, Torres A, Pedro-Botet ML, Ardanuy C, Muñoz P, Marimón JM.

Int J Infect Dis. 2020 Jan;90:161-166. doi: 10.1016/j.ijid.2019.10.032. Epub 2019 Nov 4.

12.

Emerging antibiotics for community-acquired pneumonia.

Liapikou A, Cilloniz C, Palomeque A, Torres T.

Expert Opin Emerg Drugs. 2019 Dec;24(4):221-231. doi: 10.1080/14728214.2019.1685494. Epub 2019 Nov 1. Erratum in: Expert Opin Emerg Drugs. 2019 Dec;24(4):i.

13.

An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria.

Cillóniz C, Dominedò C, Torres A.

Curr Opin Infect Dis. 2019 Dec;32(6):656-662. doi: 10.1097/QCO.0000000000000596.

PMID:
31567412
14.

Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients.

Cillóniz C, Dominedò C, Álvarez-Martínez MJ, Moreno A, García F, Torres A, Miro JM.

Expert Rev Anti Infect Ther. 2019 Oct;17(10):787-801. doi: 10.1080/14787210.2019.1671823. Epub 2019 Oct 4. Review.

PMID:
31550942
15.

Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia.

Torres A, Ceccato A, Ferrer M, Gabarrus A, Sibila O, Cilloniz C, Mendez R, Menendez R, Bermejo-Martin J, Niederman MS.

J Clin Med. 2019 Sep 13;8(9). pii: E1461. doi: 10.3390/jcm8091461.

16.

Ventilator-Associated Pneumonia and PaO2/FIO2 Diagnostic Accuracy: Changing the Paradigm?

Ferrer M, Sequeira T, Cilloniz C, Dominedo C, Bassi GL, Martin-Loeches I, Torres A.

J Clin Med. 2019 Aug 14;8(8). pii: E1217. doi: 10.3390/jcm8081217.

17.

Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia.

Cillóniz C, de la Calle C, Dominedò C, García-Vidal C, Cardozo C, Gabarrús A, Marco F, Torres A, Soriano A.

J Clin Med. 2019 Aug 1;8(8). pii: E1150. doi: 10.3390/jcm8081150.

18.

Ceftobiprole for the treatment of pneumonia.

Cillóniz C, Dominedò C, Garcia-Vidal C, Torres A.

Rev Esp Quimioter. 2019 Sep;32 Suppl 3:17-23. Review.

19.

Non-invasive ventilation in palliative care: a systematic review.

Diaz de Teran T, Barbagelata E, Cilloniz C, Nicolini A, Perazzo T, Perren A, Ocak Serin S, Scharffenberg M, Fiorentino G, Zaccagnini M, Khatib MI, Papadakos P, Rezaul Karim HM, Solidoro P, Esquinas A.

Minerva Med. 2019 Dec;110(6):555-563. doi: 10.23736/S0026-4806.19.06273-6. Epub 2019 Jul 30.

PMID:
31359741
20.

Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.

Venkatesan S, Myles PR, Bolton KJ, Muthuri SG, Al Khuwaitir T, Anovadiya AP, Azziz-Baumgartner E, Bajjou T, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Chinbayar T, Cilloniz C, Denholm JT, Dominguez SR, Duarte PAD, Dubnov-Raz G, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Higuera Iglesias AL, Hoeger PH, Hu XY, Islam QT, Jiménez MF, Keijzers G, Khalili H, Kusznierz G, Kuzman I, Langenegger E, Lankarani KB, Leo YS, Libster RP, Linko R, Madanat F, Maltezos E, Mamun A, Manabe T, Metan G, Mickiene A, Mikić D, Mohn KGI, Oliva ME, Ozkan M, Parekh D, Paul M, Rath BA, Refaey S, Rodríguez AH, Sertogullarindan B, Skręt-Magierło J, Somer A, Talarek E, Tang JW, To K, Tran D, Uyeki TM, Vaudry W, Vidmar T, Zarogoulidis P; PRIDE Consortium Investigators , Nguyen-Van-Tam JS.

J Infect Dis. 2020 Jan 14;221(3):356-366. doi: 10.1093/infdis/jiz152.

PMID:
31314899
21.

Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia.

Cillóniz C, Dominedò C, Ielpo A, Ferrer M, Gabarrús A, Battaglini D, Bermejo-Martin J, Meli A, García-Vidal C, Liapikou A, Singer M, Torres A.

J Clin Med. 2019 Jul 2;8(7). pii: E961. doi: 10.3390/jcm8070961.

22.

Emerging strategies for the noninvasive diagnosis of nosocomial pneumonia.

Liapikou A, Cillóniz C, Torres A.

Expert Rev Anti Infect Ther. 2019 Jul;17(7):523-533. doi: 10.1080/14787210.2019.1635010. Epub 2019 Jun 25.

23.

Lymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired Pneumonia.

Ceccato A, Panagiotarakou M, Ranzani OT, Martin-Fernandez M, Almansa-Mora R, Gabarrus A, Bueno L, Cilloniz C, Liapikou A, Ferrer M, Bermejo-Martin JF, Torres A.

J Clin Med. 2019 Jun 13;8(6). pii: E843. doi: 10.3390/jcm8060843.

24.

Pure Viral Sepsis Secondary to Community-Acquired Pneumonia in Adults: Risk and Prognostic Factors.

Cillóniz C, Dominedò C, Magdaleno D, Ferrer M, Gabarrús A, Torres A.

J Infect Dis. 2019 Aug 30;220(7):1166-1171. doi: 10.1093/infdis/jiz257.

25.

Evaluation of the Magicplex™ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults.

Zboromyrska Y, Cillóniz C, Cobos-Trigueros N, Almela M, Hurtado JC, Vergara A, Mata C, Soriano A, Mensa J, Marco F, Vila J.

Front Cell Infect Microbiol. 2019 Mar 12;9:56. doi: 10.3389/fcimb.2019.00056. eCollection 2019.

26.

Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia.

Cillóniz C, Dominedò C, Torres A.

Crit Care. 2019 Mar 9;23(1):79. doi: 10.1186/s13054-019-2371-3. Review.

27.

PES Pathogens in Severe Community-Acquired Pneumonia.

Cillóniz C, Dominedò C, Nicolini A, Torres A.

Microorganisms. 2019 Feb 12;7(2). pii: E49. doi: 10.3390/microorganisms7020049. Review.

28.

Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.

Ceccato A, Cilloniz C, Martin-Loeches I, Ranzani OT, Gabarrus A, Bueno L, Garcia-Vidal C, Ferrer M, Niederman MS, Torres A.

Chest. 2019 Apr;155(4):795-804. doi: 10.1016/j.chest.2018.11.006. Epub 2018 Nov 22.

29.

Nucleolar Relocalization of RBM14 by Influenza A Virus NS1 Protein.

Beyleveld G, Chin DJ, Moreno Del Olmo E, Carter J, Najera I, Cillóniz C, Shaw ML.

mSphere. 2018 Nov 14;3(6). pii: e00549-18. doi: 10.1128/mSphereDirect.00549-18.

30.

Reply to Head and Keynan.

Cillóniz C, Miro JM, Torres A.

Clin Infect Dis. 2019 Apr 8;68(8):1433-1434. doi: 10.1093/cid/ciy894. No abstract available.

31.

Community-acquired pneumonia as an emergency condition.

Cillóniz C, Dominedò C, Garcia-Vidal C, Torres A.

Curr Opin Crit Care. 2018 Dec;24(6):531-539. doi: 10.1097/MCC.0000000000000550. Review.

PMID:
30239410
32.

Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART.

Cillóniz C, Ielpo A, Torres A.

Curr Infect Dis Rep. 2018 Sep 10;20(11):46. doi: 10.1007/s11908-018-0652-7. Review.

33.

Drugs that increase the risk of community-acquired pneumonia: a narrative review.

Liapikou A, Cilloniz C, Torres A.

Expert Opin Drug Saf. 2018 Oct;17(10):991-1003. doi: 10.1080/14740338.2018.1519545. Epub 2018 Sep 17. Review.

34.

Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia.

Cillóniz C, Liapikou A, Martin-Loeches I, García-Vidal C, Gabarrús A, Ceccato A, Magdaleno D, Mensa J, Marco F, Torres A.

PLoS One. 2018 Jul 18;13(7):e0200504. doi: 10.1371/journal.pone.0200504. eCollection 2018.

35.

Clinical Approach to Community-acquired Pneumonia.

Cillóniz C, Rodríguez-Hurtado D, Nicolini A, Torres A.

J Thorac Imaging. 2018 Sep;33(5):273-281. doi: 10.1097/RTI.0000000000000343. Review.

PMID:
30005000
36.

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients.

Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, Faverio P, Cilloniz C, Rodriguez-Cintron W, Aliberti S; GLIMP.

Eur Respir J. 2018 Aug 9;52(2). pii: 1701190. doi: 10.1183/13993003.01190-2017. Print 2018 Aug.

37.

Community-acquired bacterial pneumonia in adult HIV-infected patients.

Cillóniz C, García-Vidal C, Moreno A, Miro JM, Torres A.

Expert Rev Anti Infect Ther. 2018 Jul;16(7):579-588. doi: 10.1080/14787210.2018.1495560. Epub 2018 Jul 12. Review.

38.

Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease.

Estirado C, Ceccato A, Guerrero M, Huerta A, Cilloniz C, Vilaró O, Gabarrús A, Gea J, Crisafulli E, Soler N, Torres A.

Respir Res. 2018 Jun 15;19(1):119. doi: 10.1186/s12931-018-0820-1.

39.

Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging.

Cillóniz C, Rodríguez-Hurtado D, Torres A.

Med Sci (Basel). 2018 Apr 30;6(2). pii: E35. doi: 10.3390/medsci6020035. Review.

40.

Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus-Infected Adult Patients: A Matched Case-Control Study.

Cillóniz C, Miguel-Escuder L, Pedro-Bonet ML, Falcó V, Lopez Y, García-Vidal C, Gabarrús A, Moreno A, Torres A, Miró JM; Legionella-HIV Researchers.

Clin Infect Dis. 2018 Aug 31;67(6):958-961. doi: 10.1093/cid/ciy314.

41.

Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review.

Torres A, Cillóniz C, Blasi F, Chalmers JD, Gaillat J, Dartois N, Schmitt HJ, Welte T.

Respir Med. 2018 Apr;137:6-13. doi: 10.1016/j.rmed.2018.02.007. Epub 2018 Feb 19. Review.

42.

Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia.

Cilloniz C, Ferrer M, Liapikou A, Garcia-Vidal C, Gabarrus A, Ceccato A, Puig de La Bellacasa J, Blasi F, Torres A.

Eur Respir J. 2018 Mar 29;51(3). pii: 1702215. doi: 10.1183/13993003.02215-2017. Print 2018 Mar.

43.

Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms.

Méndez R, Menéndez R, Cillóniz C, Amara-Elori I, Amaro R, González P, Posadas T, Gimeno A, España PP, Almirall J, Torres A.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):370-378. doi: 10.1164/rccm.201709-1908OC.

44.

Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients.

Vergara A, Cilloniz C, Luque N, Garcia-Vidal C, Tejero J, Perelló R, Lucena CM, Torres A, Marcos MA.

Eur Respir J. 2018 Feb 7;51(2). pii: 1701332. doi: 10.1183/13993003.01332-2017. Print 2018 Feb. No abstract available.

45.

Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients.

Ferrer M, Travierso C, Cilloniz C, Gabarrus A, Ranzani OT, Polverino E, Liapikou A, Blasi F, Torres A.

PLoS One. 2018 Jan 25;13(1):e0191721. doi: 10.1371/journal.pone.0191721. eCollection 2018.

46.

Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis.

De la Calle C, Ternavasio-de la Vega HG, Morata L, Marco F, Cardozo C, García-Vidal C, Del Rio A, Cilloniz C, Torres A, Martínez JA, Mensa J, Soriano A.

J Infect. 2018 Apr;76(4):342-347. doi: 10.1016/j.jinf.2018.01.003. Epub 2018 Jan 31.

47.

Predictors of treatment failure and clinical stability in patients with community acquired pneumonia.

Morley D, Torres A, Cillóniz C, Martin-Loeches I.

Ann Transl Med. 2017 Nov;5(22):443. doi: 10.21037/atm.2017.06.54. Review.

48.

Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress.

Garcia-Basteiro AL, Wong E, Van Oort PM, Cilloniz C, Migliori GB, Singanayagam A.

J Thorac Dis. 2017 Nov;9(Suppl 16):S1559-S1562. doi: 10.21037/jtd.2017.11.39. No abstract available.

49.

Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality.

Bermejo-Martin JF, Cilloniz C, Mendez R, Almansa R, Gabarrus A, Ceccato A, Torres A, Menendez R; NEUMONAC group.

EBioMedicine. 2017 Oct;24:231-236. doi: 10.1016/j.ebiom.2017.09.023. Epub 2017 Sep 21.

50.

Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia.

Liapikou A, Cillóniz C, Torres A.

Expert Opin Investig Drugs. 2017 Nov;26(11):1239-1248. doi: 10.1080/13543784.2017.1385761. Epub 2017 Oct 3. Review.

PMID:
28952384

Supplemental Content

Loading ...
Support Center